Pfizer Inc. (PFE) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 5YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 5Y.
- Score
- 14/100
- 5Y CAGR
- 8.5%
- Median YoY
- 2%
- YoY volatility
- σ 50.8pp· choppy
- Quarters ≥ 20%
- 7 of 20
- Negative quarters
- 9
- Valuation vs own 5Y history
- P/S 2.2x · 5Y median 2.5x · 10th percentile
How this score is computed
- Quarters at or above 20%: 7 of 20 → 14 of 40 pts
- Steadiness (typical swing 50.8pp) → 0 of 25 pts
- Pace (median 2% YoY) → 0 of 20 pts
- Latest quarter (5.4% YoY) → 0 of 15 pts
- Score: 14 of 100
Annual revenue · last 11 fiscal years
Quarterly YoY revenue growth vs the 20% line · 5Y
P/S multiple vs its 5Y median · context only
Across metrics · 5Y
| Metric | 5Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 8.5% | 2% | 50.8pp | 7 of 20 | 9 |
| EPSEPS | -3.5% | 25% | 3001.4pp | 8 of 16 | 7 |
| Op cash flowOperating cash flow | -4.1% | 8.6% | 117.8pp | 8 of 18 | 8 |
| EBITDAEBITDA | 8.1% | 19.7% | 400.8pp | 9 of 19 | 9 |
| FCFFree cash flow | -4.8% | 30.7% | 184.3pp | 10 of 18 | 7 |
Reported figures over 5Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: PFE on the compounders surface · All compounders, ranked
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla